Health
New weight-loss shot shows major fat reduction, but experts urge caution
NEWYou can now listen to Fox News articles!
An experimental medication was shown to help boost weight loss by up to 20%, a study found.
Eloralintide, a once-weekly injectable manufactured by Eli Lilly in Indianapolis, led to “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes, according to a press release.
The drug was generally well-tolerated by the study participants.
An experimental medication was shown to help boost weight loss by up to 20%, a study found. (iStock)
The Phase 2 trial, which was funded by Eli Lilly, included 263 adults. After 48 weeks, they had lost between 9.5% and 20.1% of their body weight, compared to 0.4% for those taking the placebo.
Treatment with eloralintide was also linked to improvements in waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation, all of which can increase cardiometabolic risk, according to the researchers.
WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT
“The weight loss we saw in the study is clinically impactful,” lead study author Liana K. Billings, M.D., director of clinical and genetics research in diabetes and cardiometabolic disease at Endeavor Health in Skokie, Illinois, said in the press release.
“With this degree of weight loss in only 48 weeks, we see people having improvement or resolution in other conditions like hypertension, hyperlipidemia, osteoarthritis, sleep apnea and more weight-related conditions.”
Eloralintide, a once-weekly injectable manufactured by Eli Lilly in Indianapolis, led to “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes. (Getty Images)
“Furthermore, in the study, we did not see a nadir or plateau of weight loss, so I would expect weight loss to continue if the study continued for a longer duration. Additionally, up to 90% of participants on eloralintide improved by at least one BMI category,” she added.
The results were published in The Lancet and presented at ObesityWeek 2025 in Atlanta, Georgia, earlier this month.
AMERICA’S FATTEST STATES REVEALED — AND HOW OZEMPIC IS CHANGING THE MAP
While popular GLP-1 drugs — including Ozempic, Wegovy, Mounjaro and Zepbound — work by mimicking the gut hormone GLP-1 (glucagon-like peptide-1), eloralintide is a selective amylin receptor agonist that works by mimicking a pancreas hormone called amylin.
Similar to GLP-1s, it helps to slow digestion, reduce appetite and control blood sugar after meals. It has not yet been FDA-approved for clinical use.
While GLP-1 drugs work by mimicking the gut hormone GLP-1, eloralintide is a selective amylin receptor agonist that works by mimicking a pancreas hormone called amylin. (iStock)
The biggest side effects noted for eloralintide were mild to moderate gastrointestinal symptoms and fatigue, the researchers noted. These effects were greater at higher doses.
“Obesity is a complex condition, and no single treatment works for everyone,” said Billings.
“To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them.”
COULD GLP-1 WEIGHT-LOSS MEDICATIONS LIKE OZEMPIC BECOME THE ‘EVERYTHING DRUG’?
Based on the trial results, the reseachers plan to launch Phase 3 clinical studies for obesity treatment by the end of this year, the president of Lilly Cardiometabolic Health confirmed to Fox News Digital. The drug is also being evaluated for use in combination with GLP-1 medications.
Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, shared some concerns about the new anti-obesity agents being developed.
“Bottom line: If an individual has an experienced and competent physician supervising their care — and driving the formation of healthy habits in addition to simply using the medication — they will lose weight,” a doctor said. (iStock)
“Between all the agents out there, there is no way any person cannot lose weight when coupled with progressive resistance training and attention to their daily macronutrient intake, even if only a little,” the doctor, who was not involved in the study, told Fox News Digital.
“Yet big pharma will continue to search for novel targets to introduce a new drug that will likely prove similarly, yet not more, efficacious than the current agents. There are enough agents out there to drive weight loss to a malnutrition status.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Osborn also noted that the lower cardiovascular risk associated with the drug was likely due to the participants losing body fat, which reduces the risk for all age-related diseases.
“Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term.”
“Bottom line: If an individual has an experienced and competent physician supervising their care — and driving the formation of healthy habits in addition to simply using the medication — they will lose weight,” he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Sue Decotiis, M.D., a medical weight-loss doctor in New York City, also shared her thoughts on eloralintide’s potential as an alternative treatment.
“It seems that the more receptor systems that are influenced, the more weight a patient can lose,” she told Fox News Digital. “This is why tirzepatide (Mounjaro, Zepbound), which hits two receptors, induced more weight loss than Ozempic and Wegovy.”
“To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them,” a researcher said. (iStock)
“In my practice, I witnessed significantly better results with tirzepatide when patients were switched from Ozempic.”
Hitting more receptors may be the answer for those patients who do not respond well or who “hit the wall” with simpler drugs, according to Decotiis, who also was not involved in the study.
“For long-term safety and results, peptide drugs show promise,” she said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Whitney Di Bona, in-house attorney and consumer safety advocate for Drugwatch, noted that while the Phase 2 results are “promising,” it is important to be cautious.
“These drugs have been used for years, but new safety concerns keep appearing,” the Florida-based expert told Fox News Digital. Some of those include a potentially serious eye condition, delayed stomach emptying, bowel obstruction and serious digestive problems, which have led to many lawsuits.
CLICK HERE FOR MORE HEALTH STORIES
“Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term,” Di Bona advised. “Even with careful studies, some risks may only become clear after the drug is used by many people.”
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
Taking a GLP-1 medication for weight loss may improve male fertility, according to experts.
Research presented this week at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, explored how obesity is strongly linked to fertility problems in men.
Excess weight can contribute to dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis — the hormone system that regulates testosterone production — and functional hypogonadism, a condition in which testosterone levels are abnormally low because of disrupted hormone signaling. These changes can also impair semen quality.
WEIGHT-LOSS MEDICATIONS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS
The researchers evaluated how GLP-1 weight-loss drugs impact reproductive hormones and metabolic outcomes, analyzing data of men between the ages of 18 and 65 who were taking one of the medications, according to a press release.
The systematic review of five randomized controlled trials focused on measuring testosterone, brain hormones involved in testosterone and sperm production, and a protein that carries sex hormones in the blood. Semen quality, weight and BMI, cholesterol and blood sugar were also measured.
Men with obesity and low testosterone linked to obesity may experience improved testosterone, sperm quality and metabolic heath while taking a GLP-1, the study found. (iStock)
The results suggested that GLP-1 medications do not suppress male hormones. Men with obesity and low testosterone linked to obesity may experience improved testosterone, sperm quality and metabolic health, especially during weight loss.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
In one four-week study, dulaglutide showed no significant changes in reproductive hormones or sexual function.
In a separate 16-week trial, liraglutide improved hormones in obese men with functional hypogonadism, meaning low testosterone was likely related to obesity. The review found that liraglutide was better for health outcomes than hormone replacement therapy.
CLICK HERE FOR MORE HEALTH STORIES
Another liraglutide study reported improved sperm concentration and count.
The study authors concluded that GLP-1s “do not appear to acutely suppress the male HPG axis and may improve reproductive hormones and semen parameters in obese hypogonadal men, largely within the context of weight loss.” (iStock)
A 24-week trial of semaglutide, known commercially as Ozempic and Wegovy, saw improvement in sperm shape and bad cholesterol, while preserving total testosterone.
As only five trials were included, the small evidence base suggests more research is necessary to prove further association.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
In an abstract of the research, the authors summed up that GLP-1s “do not appear to acutely suppress the male HPG axis and may improve reproductive hormones and semen parameters in obese hypogonadal men, largely within the context of weight loss.”
“However, evidence remains limited and heterogeneous, underscoring the need for larger RCTs explicitly powered to assess male reproductive outcomes,” they wrote.
“This provides early evidence that GLP-1 medications taken by obese men with hypogonadism/low testosterone (low T) improves testosterone levels,” one doctor said. (iStock)
Dr. Anthony Puopolo, men’s health expert and lead medical provider for RexMD, reflected on these findings in an interview with Fox News Digital.
“This provides early evidence that GLP-1 medications taken by obese men with hypogonadism/low testosterone (low T) improves testosterone levels,” he said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
While more research is necessary, Pupolo, who was not involved in the study, shared his optimism about how GLP-1s can play a role in improving male fertility.
“If this finding continues to gain evidence, GLP-1s might be a better option for low T than testosterone replacement therapy (TRT) in obese men – as GLP-1 medications preserve fertility, whereas TRT tends to be harmful to male reproductive/sperm function,” he added.
Health
Measles-infected traveler may have exposed passengers at LAX and nearby hotel, health officials warn
NEWYou can now listen to Fox News articles!
A traveler infected with measles may have exposed passengers at Los Angeles International Airport and guests at a nearby hotel after arriving in Los Angeles County earlier this month, health officials said Wednesday.
The Los Angeles County Department of Public Health said it is investigating a confirmed measles case involving a traveler who arrived aboard Cathay Pacific Flight CX 884 on June 11. The traveler was infectious while passing through Los Angeles County, potentially exposing others at LAX and the Hilton Los Angeles Airport Hotel.
The case marks the sixth measles infection reported in Los Angeles County this year. Health officials said the risk of exposure could increase as summer travel ramps up and Los Angeles welcomes international visitors for FIFA World Cup events being held in the region.
MEASLES CASES CONFIRMED AT FOUR MAJOR US AIRPORTS ACROSS COUNTRY AMID PEAK HOLIDAY TRAVEL
A 3D illustration shows measles virus particles. (iStock)
According to health officials, anyone who was at the Tom Bradley International Terminal between 10 a.m. and noon on June 11 may have been exposed. Officials also identified a potential exposure at the Hilton Los Angeles Airport Hotel, located at 5711 W. Century Blvd., between 11:15 a.m. and 12:15 p.m. that same day.
The Centers for Disease Control and Prevention is working with local health departments to notify passengers who were seated near the infected traveler on the international flight.
People who were at either location during the listed times could develop symptoms between seven and 21 days after exposure, officials said. The last day to monitor for symptoms is July 2.
AT LEAST 46 CHILDREN DEAD AMID MEASLES OUTBREAK AS VIRUS SPREADS GLOBALLY
Los Angeles International Airport is seen in Los Angeles, California. Health officials said a traveler infected with measles may have exposed passengers at LAX on June 11. (Michael Yanow/NurPhoto)
“As measles cases increase, it is important that residents take steps to make sure they are fully protected,” Los Angeles County Health Officer Dr. Muntu Davis said. “The MMR vaccine is the safest and most reliable way to prevent measles and protect yourself, your family, and your community.”
Travelers exit a terminal at Los Angeles International Airport in Los Angeles on Monday, March 23, 2026. (Ethan Swope/AP Photo)
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Symptoms include fever, cough, runny nose, red and watery eyes, followed by a rash that typically begins on the face before spreading to the rest of the body.
Fox News Digital reached out to the Los Angeles County Department of Public Health for additional comment but did not receive a response.
-
Pennsylvania4 minutes ago7 Off-The-Grid Pennsylvania Towns To Visit In 2026
-
Rhode Island7 minutes agoR.I. Democratic Committee issues no endorsement for governor or lieutenant governor – The Boston Globe
-
South-Carolina12 minutes agoWith 77 days until South Carolina football kicks off 2026 season, a look back at No. 77 George Schecterly
-
South Dakota19 minutes agoSaturday Boredom Busters: June 20
-
Tennessee22 minutes agoThings to do in the Chattanooga area this week include Chickapalooza, Amy Grant, Summerween | Chattanooga Times Free Press
-
Texas27 minutes agoSee how Texas medical schools rank among the world’s best for 2026
-
Utah34 minutes agoUtah marks a year of battling measles, with no clear end in sight
-
Vermont34 minutes ago‘The Great Bennington Battle and Vermont’: Pawlet and Rupert Historical Societies to host historian Howard Coffin
